Promising results with neoadjuvant atezolizumab for stage IB-IIIB NSCLC

Neoadjuvant atezolizumab resulted in a pathological response (MPR) in 21% of patients with resectable stage IB-IIIB NSCLC and significantly improvement in surgical outcomes with a high degree of R0 resection of 91% according to data from the primary analysis of the phase II study Cancer Mutation Consortium (LCMC) 3.